Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL186560 | 1.00 | MEN1 (0.33) | MEN1HSP90AA1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15896789 | 0.99 | MEN1 (0.31) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL15896787 | 0.99 | MEN1 (0.31) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Bromide SCHEMBL186494 | 0.88 | MEN1 (0.35) | MEN1HSP90AA1KMT2ASMN1; SMN2ALDH1A1 | |
| Bromide SCHEMBL186465 | 0.86 | MEN1 (0.36) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL15896738 | 0.86 | MEN1 (0.33) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL15896752 | 0.86 | MEN1 (0.33) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL15896805 | 0.85 | MEN1 (0.35) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| SCHEMBL15896788 | 0.85 | MEN1 (0.35) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Bromide SCHEMBL186496 | 0.84 | SMN1; SMN2 (0.40) | MEN1HSP90AA1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071661-A1 | Ionic Liquid Solvents | DUBLIN CITY UNIVERSITY (IE) | 2012-03-22 | — | — | US | claimed |
| EP-2401258-A1 | IONIC LIQUID SOLVENTS | Dublin City University (IE) | 2012-01-04 | — | — | EP | claimed |
| WO-2010097412-A1 | IONIC LIQUID SOLVENTS | DUBLIN CITY UNIVERSITY (IE) | 2010-09-02 | — | — | WO | claimed |
| US-8785655-B2 | Ionic liquid solvents | DUBLIN CITY UNIVERSITY (IE) | 2014-07-22 | — | — | US | disclosed |
| US-20120071661-A1 | Ionic Liquid Solvents | DUBLIN CITY UNIVERSITY (IE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071661-A1 | Ionic Liquid Solvents | EBP, PAICS, HACD3 | MEN1 3011/4885HSP90AA1 3719/4885KMT2A 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.